3741468

Discovery of afimetoran, a small molecule dual antagonist of the toll-like receptors 7 and 8 (TLR7/8) advanced to clinical evaluation in patients with lupus

Date
August 21, 2022

The toll-like receptors (TLRs) are integral to the innate immune system, serving as pattern recognition receptors for the early detection of molecular signatures presented by pathogenic sources such as bacteria and viruses. The TLRs can also be activated by endogenous ligands released from stressed or damaged cells. TLR7 and TLR8 are endosomally-localized members of the TLR family that respond to single-stranded RNA by recruitment of the cytosolic adaptor protein MyD88 and engagement of IRAK1/4. Subsequent downstream activation of the NFκB and IRF pathways leads to induction of pro-inflammatory cytokines and production of type-I interferons respectively. Undesired activation of TLR7/8 via self-motifs is believed to be a driver of lupus and other autoimmune disorders and has been implicated in the development of steroid resistance in some patients. In our search for antagonists of endosomal TLRs, small molecule hits originating from high throughput screening were optimized through structure-based design, aided by X-ray co-crystallographic structures. This presentation will detail those efforts, which culminated in the identification of afimetoran as a potent and selective dual antagonist of TLR7/8. Afimetoran demonstrated excellent pharmacokinetic profiles in non-clinical species and was profiled in MRL/lpr and NZB/W mouse models of lupus, where it was highly effective as monotherapy treatment at controlling disease and even reversing the signs of established disease. Combination of afimetoran with prednisolone showed improved results relative to either monotherapy in mouse lupus models as well as in human blood assays measuring inhibition of TLR7 or TLR8 responses. With successful completion of Phase I studies revealing a favorable human pharmacokinetic and pharmacodynamic profile, afimetoran was advanced into clinical evaluation in patients with cutaneous lupus (CLE) or systemic lupus (SLE).

Related Products

Thumbnail for Optimization of 4H-pyrrolo[3,2-d]thiazole based antagonists of toll-like receptors 7 and 8 (TLR7/8) for the treatment of lupus
Optimization of 4H-pyrrolo[3,2-d]thiazole based antagonists of toll-like receptors 7 and 8 (TLR7/8) for the treatment of lupus
A primary defect in lupus patients is the accumulation of apoptotic debris enriched in RNA ligands capable of activating TLR7 and TLR8, especially as the ligands form immune complexes with pre-existing autoantibodies…
Thumbnail for Exploration of carbazole-based antagonists of toll-like receptors 7 and 8 (TLR7/8) generated via structure-guided evolution of an indole series
Exploration of carbazole-based antagonists of toll-like receptors 7 and 8 (TLR7/8) generated via structure-guided evolution of an indole series
Pattern recognition receptors (PRRs) of the innate immune system are an important part of frontline immune surveillance, recognizing signals from infection and cellular stress…
Thumbnail for Discovery of selective small-molecule dual antagonists of toll-like receptors 7 and 8 (TLR7/8) through optimization of an indole scaffold and C-2 bicyclic heteroarene substituents | Poster Board #503
Discovery of selective small-molecule dual antagonists of toll-like receptors 7 and 8 (TLR7/8) through optimization of an indole scaffold and C-2 bicyclic heteroarene substituents | Poster Board #503
The innate immune system employs toll-like receptors (TLRs) to identify signs of cellular stress and infection through the recognition of damage-associated and pathogen-associated molecular patterns, resulting in upregulation of immune pathways…
Thumbnail for Structure-based design of 2-(pyridin-2(1H)-one)indoles as antagonists of the toll-like receptors TLR7 and TLR8 for the treatment of autoimmune diseases
Structure-based design of 2-(pyridin-2(1H)-one)indoles as antagonists of the toll-like receptors TLR7 and TLR8 for the treatment of autoimmune diseases
The toll-like receptors (TLRs) serve key roles in the innate immune system through their recognition of pathogen- and danger-associated molecular patterns (PAMPs/DAMPs)…